title: Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.
abstract: Lithium is one of the most widely used mood-stabilizing agents for the treatment of bipolar disorder. Although the underlying mechanism(s) of this mood stabilizer remains controversial, recent evidence linking lithium to neurotrophic/neuroprotective effects (Choi and Sung (2000) 1475, 225-230; Davies et al. (2000) 351, 95-105) suggests novel benefits of this drug in addition to mood stabilization. Here, we report that both lithium as well as valproic acid (VPA) inhibit beta-amyloid peptide (Abeta) production in HEK293 cells stably transfected with Swedish amyloid precursor protein (APP)(751) and in the brains of the PDAPP (APP(V717F)) Alzheimer's disease transgenic mouse model at clinically relevant plasma concentrations. Both lithium and VPA are known to be glycogen synthase kinase-3 (GSK3) inhibitors. Our studies reveal that GSK3beta is a potential downstream kinase, which modulates APP processing because inhibition of GSK3 activity by either a dominant negative GSK3beta kinase-deficient construct or GSK3beta antisense oligonucleotide mimics lithium and VPA effects. Moreover, lithium treatment abolished GSK3beta-mediated Abeta increase in the brains of GSK3beta transgenics and reduced plaque burden in the brains of the PDAPP (APP(V717F)) transgenic mice.
authors.affiliation: Lilly Research Laboratories, Indianapolis, Indiana 46285, USA. su_yuan@lilly.com
authors.forename: Yuan
authors.initials: Y
authors.lastname: Su
authors.forename: John
authors.initials: J
authors.lastname: Ryder
authors.forename: Baolin
authors.initials: B
authors.lastname: Li
authors.forename: Xin
authors.initials: X
authors.lastname: Wu
authors.forename: Niles
authors.initials: N
authors.lastname: Fox
authors.forename: Pat
authors.initials: P
authors.lastname: Solenberg
authors.forename: Kellie
authors.initials: K
authors.lastname: Brune
authors.forename: Steven
authors.initials: S
authors.lastname: Paul
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhou
authors.forename: Feng
authors.initials: F
authors.lastname: Liu
authors.forename: Binhui
authors.initials: B
authors.lastname: Ni
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D000818:Animals; D001714:Bipolar Disorder / Q000188:drug therapy; D001921:Brain / Q000378:metabolism; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005799:Genes, Dominant; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D006801:Humans; D008094:Lithium / Q000494:pharmacology*; D051379:Mice; D008822:Mice, Transgenic; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D011499:Protein Processing, Post-Translational; D014635:Valproic Acid / Q000494:pharmacology
chemical_list: D016564:Amyloid beta-Protein Precursor; D004791:Enzyme Inhibitors; D016376:Oligonucleotides, Antisense; D014635:Valproic Acid; D008094:Lithium; C000605506:GSK3B protein, human; D000071679:Glycogen Synthase Kinase 3 beta; C000605507:Gsk3b protein, mouse; D038362:Glycogen Synthase Kinase 3